WoS
🏆 JCR Q2 · JIF 3,1
YÖKSİS Eşleşti
2025 Editorial material 1. Yazar
Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?
FUTURE ONCOLOGY
·
Cilt 21, s. 3589-3592
·
ISSN 1479-6694
Prof. Dr. RAFİYE ÇİFTÇİLER
· 2 yazar
WoS
🏆 JCR Q2 · JIF 3
YÖKSİS Eşleşti
2022 Review 3. Yazar
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension
EXPERT OPINION ON DRUG SAFETY
·
Cilt 21, s. 525-539
·
ISSN 1474-0338
Prof. Dr. BANU BOZKURT
· 9 yazar
WoS
🏆 JCR Q2 · JIF 2,4 2021 Article 5. Yazar
Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center
EPILEPSY & BEHAVIOR
·
Cilt 116
·
ISSN 1525-5050
Dr. Öğr. Üyesi SÜLEYMAN ŞAHİN
· 6 yazar